These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 21546955)

  • 41. Vismodegib: a guide to its use in locally advanced or metastatic basal cell carcinoma.
    Lyseng-Williamson KA; Keating GM
    Am J Clin Dermatol; 2013 Feb; 14(1):61-4. PubMed ID: 23329081
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sonidegib for the treatment of advanced basal cell carcinoma: a comprehensive review of sonidegib and the BOLT trial with 12-month update.
    Chen L; Silapunt S; Migden MR
    Future Oncol; 2016 Sep; 12(18):2095-105. PubMed ID: 27189494
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Precision medicine and precision therapeutics: hedgehog signaling pathway, basal cell carcinoma and beyond.
    Mohan SV; Chang AL
    Semin Cutan Med Surg; 2014 Jun; 33(2):68-71. PubMed ID: 25085664
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma.
    Proctor AE; Thompson LA; O'Bryant CL
    Ann Pharmacother; 2014 Jan; 48(1):99-106. PubMed ID: 24259609
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hedgehog Pathway Inhibition.
    Sekulic A; Von Hoff D
    Cell; 2016 Feb; 164(5):831. PubMed ID: 26919418
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Managing adverse effects by dose reduction during routine treatment of locally advanced basal cell carcinoma with the hedgehog inhibitor vismodegib: a single centre experience.
    Woltsche N; Pichler N; Wolf I; Di Meo N; Zalaudek I
    J Eur Acad Dermatol Venereol; 2019 Apr; 33(4):e144-e145. PubMed ID: 30472793
    [No Abstract]   [Full Text] [Related]  

  • 47. [Hedgehog inhibitors. New promising treatment of advanced basal cell carcinoma].
    Wolodarski M; Lapins J; Hansson J
    Lakartidningen; 2013 Apr 24-May 6; 110(17-18):886-8. PubMed ID: 23717940
    [No Abstract]   [Full Text] [Related]  

  • 48. Tumor Architecture and Notch Signaling Modulate Drug Response in Basal Cell Carcinoma.
    Eberl M; Mangelberger D; Swanson JB; Verhaegen ME; Harms PW; Frohm ML; Dlugosz AA; Wong SY
    Cancer Cell; 2018 Feb; 33(2):229-243.e4. PubMed ID: 29395868
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tumor shrinkage by cyclopamine tartrate through inhibiting hedgehog signaling.
    Fan Q; Gu D; He M; Liu H; Sheng T; Xie G; Li CX; Zhang X; Wainwright B; Garrossian A; Garrossian M; Gardner D; Xie J
    Chin J Cancer; 2011 Jul; 30(7):472-81. PubMed ID: 21718593
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Targeting the hedgehog pathway to treat basal cell carcinoma.
    Geeraert P; Williams JS; Brownell I
    J Drugs Dermatol; 2013 May; 12(5):519-23. PubMed ID: 23652945
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of combination of notch inhibitor plus hedgehog inhibitor or Wnt inhibitor on growth of leukemia cells.
    Okuhashi Y; Itoh M; Nara N; Tohda S
    Anticancer Res; 2011 Mar; 31(3):893-6. PubMed ID: 21498710
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Assessment of the adverse events related to hedgehog pathway inhibitor therapy for basal cell carcinoma: A single-centre retrospective study.
    Villani A; Fabbrocini G; Costa C; Cappello M; Scalvenzi M
    Australas J Dermatol; 2021 May; 62(2):e296-e297. PubMed ID: 33040336
    [No Abstract]   [Full Text] [Related]  

  • 53. Dose reduction during routine treatment of locally advanced basal cell carcinoma with the hedgehog inhibitor sonidegib to manage adverse effects: A retrospective case series.
    Villani A; Costa C; Fabbrocini G; Ruggiero A; Scalvenzi M
    J Am Acad Dermatol; 2021 Apr; 84(4):e211-e212. PubMed ID: 33301802
    [No Abstract]   [Full Text] [Related]  

  • 54. Design and synthesis of inhibitors of Hedgehog signaling based on the alkaloid cyclopamine.
    Winkler JD; Isaacs A; Holderbaum L; Tatard V; Dahmane N
    Org Lett; 2009 Jul; 11(13):2824-7. PubMed ID: 19552464
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Locally advanced and metastatic basal cell carcinoma: molecular pathways, treatment options and new targeted therapies.
    Ruiz Salas V; Alegre M; Garcés JR; Puig L
    Expert Rev Anticancer Ther; 2014 Jun; 14(6):741-9. PubMed ID: 24611655
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Vismodegib and the hedgehog pathway: a new treatment for basal cell carcinoma.
    Cirrone F; Harris CS
    Clin Ther; 2012 Oct; 34(10):2039-50. PubMed ID: 23036338
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inhibition of hedgehog signaling reduces the side population in human malignant mesothelioma cell lines.
    Kim HA; Kim MC; Kim NY; Kim Y
    Cancer Gene Ther; 2015 Aug; 22(8):387-95. PubMed ID: 26206198
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Hedgehog inhibitor gets landmark skin cancer approval, but questions remain for wider potential.
    Guha M
    Nat Rev Drug Discov; 2012 Mar; 11(4):257-8. PubMed ID: 22460111
    [No Abstract]   [Full Text] [Related]  

  • 59. Hair loss and Hedgehog inhibitors: a class effect?
    Ferguson JS; Hannam S; Toholka R; Chong AH; Magee J; Foley P
    Br J Dermatol; 2015 Jul; 173(1):262-4. PubMed ID: 25523648
    [No Abstract]   [Full Text] [Related]  

  • 60. Development of taladegib as a sonic hedgehog signaling pathway inhibitor.
    Jin G; Sivaraman A; Lee K
    Arch Pharm Res; 2017 Dec; 40(12):1390-1393. PubMed ID: 29159582
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.